Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma [see comments] NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma [see comments]

Blood. 1999 Jun 15;93(12):4044-58. Unique Identifier : AIDSLINE MED/99290758
Monini P; Colombini S; Sturzl M; Goletti D; Cafaro A; Sgadari C; Butto S; Franco M; Leone P; Fais S; Leone P; Melucci-Vigo G; Chiozzini C; Carlini F; Ascherl G; Cornali E; Zietz C; Ramazzotti E; Ensoli F; Andreoni M; Pezzotti P; Rezza G; Yarchoan R; Gallo RC; Ensoli B; Laboratory of Virology, Istituto Superiore di Sanita, Rome,; Italy.


Abstract: Patients with Kaposi's sarcoma (KS) have a human herpesvirus-8 (HHV-8) load higher than patients without KS and present a CD8(+) T-cell activation with production of Th1-type cytokines both in tissues and peripheral blood mononuclear cells (PBMC). Because in tissues of KS patients detection of inflammatory cytokines (IC) can precede detection of HHV-8 DNA and because signs of immunoactivation and/or dysregulation can precede KS development, we investigated the effect of IC on HHV-8 infection. To achieve this goal, PBMC and purified cell populations from 45 patients with KS and 45 patients at risk of KS were analyzed for HHV-8 DNA and/or gene expression and for cell survival, growth, and phenotype before or after culture with or without the IC increased in KS. The results indicate that PBMC that are polymerase chain reaction (PCR)-positive at day 0 generally loose the virus upon culture. However, the presence of IC maintains HHV-8 DNA load in cultured cells. In addition, IC increase viral load to detectable levels in PBMC from serologically positive patients that were PCR-negative before culture. gamma Interferon is sufficient for these effects, whereas tumor necrosis factor and interleukin-6 have little or no activity. The increase of HHV-8 DNA by IC is observed after short-term (7 days) or long-term (28 days) culture of the cells and occurs in one or both of the two circulating cell types that are infected in vivo: B cells and monocytes. In both cases it is associated with lytic gene expression, suggesting that virus reactivation is one of the most likely mechanisms for the effect of IC on virus load. However, IC have also effects on the cells target of HHV-8 infection, because they increase B-cell survival and induce the growth and differentiation of monocytes into KS-like spindle cells with markers of endothelial macrophages. Because cells with markers of endothelial macrophages are present in blood and lesions from KS patients and are infected by HHV-8, these data may explain the high HHV-8 load associated with KS development and suggest that infected monocytes may carry the virus to tissues, transmit the infection, or differentiate in loco in spindle cells with endothelial macrophage markers.
Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/COMPLICATIONS B-Lymphocytes/CYTOLOGY/*VIROLOGY Cell Division Cell Survival Cells, Cultured Cytokines/METABOLISM/*PHARMACOLOGY DNA, Viral/ANALYSIS Herpesvirus, Kaposi Sarcoma-Associated/*GROWTH & DEVELOPMENT/ GENETICS Human Male Monocytes/CYTOLOGY/*VIROLOGY Phenotype Polymerase Chain Reaction Sarcoma, Kaposi/COMPLICATIONS/*METABOLISM/VIROLOGY Support, Non-U.S. Gov't *Virus ActivationKWDjournalarticleacquiredimmunodeficiencysyndrome/complicationsb-lymphocytes/cytology/KWDvirologycelldivisioncellsurvivalcells,culturedcytokines/metabolism/KWDpharmacologydna,viral/analysisherpesvirus,kaposisarcoma-associated/KWDgrowth&development/geneticshumanmalemonocytes/cytology/KWDvirologyphenotypepolymerasechainreactionsarcoma,kaposi/complications/KWDmetabolism/virologysupport,non-uKWDsKWDgov'tKWDvirusactivation
Comment in: Blood 1999 Jun 15;93(12):4031-3
990930
A9991279

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .